 |
|
Experts predict high mortality rates from pulmonary fibrosis will continue to rise
August 01, 2007Mortality rates from pulmonary fibrosis (PF) have increased significantly in recent years, and are predicted to continue to rise, according to researchers from the University of Colorado.
Between 1992 and 2003, the age-adjusted mortality rate from PF--an often fatal disease which involves scarring of the lung--rose by nearly 28.4 percent in men, and 41.3 percent in women. Over the same time period, an increasing percentage of patients with PF died of the disease itself rather than of coexisting conditions.
"Rates rise with increasing age, are highest among older people, and are consistently higher in men than in women," wrote the researchers. "However, mortality rates in women with PF are climbing more rapidly than in men."
The study, led by Amy Olsen, M.D., M.S.P.H., of the University of Colorado Health Sciences Center, appears in the August 1, 2007, issue to the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
Dr. Olson and five colleagues analyzed the cause of death listed on death certificates for more than 28 million decedents using data compiled by the National Center for Health Statistics. Of that larger group, more than 175,000 deaths were linked to PF. In developing a model to predict future mortality rates, the researchers applied a multivariable analysis to current data, finding a predicted significant increase in men over the age of 65 and for women in all age categories.
"Our study is the first large-scale study to examine age-, sex-, race-, and ethnicity-stratified mortality rates in decedents with PF," said Dr. Olson.
In addition to finding a large disparity in mortality rates among women and men, which researchers suggest may be attributable to changes in historically gendered smoking patterns, they also found significant differences among racial and ethnic lines. Age-adjusted mortality rates among whites were higher than among blacks or Hispanics and increasing more quickly than in other racial and ethnic groups. Although previous studies have suggested that whites are more likely to be diagnosed with PF, differences in race or ethnicity "may also play a role in susceptibility," the researchers note, and merit further examination.
The investigators also found significant geographical variation in mortality rates, but were unable to determine whether these differences represent true differences in mortality rates, which would suggest an environmental factor in the pathogenesis of PF, or if differences reflect variation in diagnostic criteria used and testing available in different localities, or variation in coding and certifying cause-of-death on death certificates.
"Although we were unable to determine the underlying cause of the geographic variation using this dataset, these differences warrant further exploration," Dr. Olson said.
Similarly, the researchers were unable to determine whether the increased percentage of patients with PF dying from the disease itself represents an improvement in treatments for commonly co-existing conditions such as cardiovascular disease, reflects diagnostic changes, or the result of a new classification system implemented in 1997 that excludes patients with more hopeful prognoses.
"Although once considered an orphan disease, our results suggest that PF should no longer be considered a rarity," Dr. Olson concluded, noting that current death rates for the disease are higher than multiple myeloma and bladder cancer "These findings indicate an important and growing problem and provide an argument for more resources focused on the pathobiology of and therapy for this disease."
American Thoracic Society
The study, led by Amy Olsen, M.D., M.S.P.H., of the University of Colorado Health Sciences Center, appears in the August 1, 2007, issue to the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
Dr. Olson and five colleagues analyzed the cause of death listed on death certificates for more than 28 million decedents using data compiled by the National Center for Health Statistics. Of that larger group, more than 175,000 deaths were linked to PF. In developing a model to predict future mortality rates, the researchers applied a multivariable analysis to current data, finding a predicted significant increase in men over the age of 65 and for women in all age categories.
"Our study is the first large-scale study to examine age-, sex-, race-, and ethnicity-stratified mortality rates in decedents with PF," said Dr. Olson.
In addition to finding a large disparity in mortality rates among women and men, which researchers suggest may be attributable to changes in historically gendered smoking patterns, they also found significant differences among racial and ethnic lines. Age-adjusted mortality rates among whites were higher than among blacks or Hispanics and increasing more quickly than in other racial and ethnic groups. Although previous studies have suggested that whites are more likely to be diagnosed with PF, differences in race or ethnicity "may also play a role in susceptibility," the researchers note, and merit further examination.
The investigators also found significant geographical variation in mortality rates, but were unable to determine whether these differences represent true differences in mortality rates, which would suggest an environmental factor in the pathogenesis of PF, or if differences reflect variation in diagnostic criteria used and testing available in different localities, or variation in coding and certifying cause-of-death on death certificates.
"Although we were unable to determine the underlying cause of the geographic variation using this dataset, these differences warrant further exploration," Dr. Olson said.
Similarly, the researchers were unable to determine whether the increased percentage of patients with PF dying from the disease itself represents an improvement in treatments for commonly co-existing conditions such as cardiovascular disease, reflects diagnostic changes, or the result of a new classification system implemented in 1997 that excludes patients with more hopeful prognoses.
"Although once considered an orphan disease, our results suggest that PF should no longer be considered a rarity," Dr. Olson concluded, noting that current death rates for the disease are higher than multiple myeloma and bladder cancer "These findings indicate an important and growing problem and provide an argument for more resources focused on the pathobiology of and therapy for this disease."
American Thoracic Society
Pulmonary Fibrosis News and Current Pulmonary Fibrosis Events RSSNote to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in
Family, friends and neighbors remember Lisa Sandler Spaeth as an active mother of two in Potomac, Md., with a lot on the go, juggling her son's baseball games and her daughter's horseback-riding lessons with numerous committee obligations, organizing women's activities at her local synagogue.
Biomarkers identified for idiopathic pulmonary fibrosis
The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.
UCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
Rare Lung Disease Cells Indicate Higher Death Risk
Large numbers of certain cells in the lungs of patients diagnosed with idiopathic pulmonary fibrosis may increase their chance of death, UC researchers have discovered.
Smoking belies milder disease but worse prognosis for IPF patients
Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.
Researchers show that fibrosis can be stopped, cured and reversed
University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed.
Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis is a disease with unknown cause with a very severe prognosis; when detected, it is already in an advanced stage.
Molecular pathway appears crucial in development of pulmonary fibrosis
A study led by Massachusetts General Hospital (MGH) researchers may have found a key mechanism underlying idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease for which transplantation is the only successful treatment.
Preventing lung scarring may extend lives of lung cancer patients
Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients - pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life.
Scleroderma Outlook Improves as Survival Increases
Individuals with scleroderma are living significantly longer today, compared with 30 years ago, and the physicians who treat this rare disease of connective tissue hope the newer drugs now on the market may extend lives even further.
More Pulmonary Fibrosis News Articles
 | Cystic Fibrosis: A Guide for Patient and Family Written by Dr. David Orenstein, director of one of the nation's leading CF centers, this one-of-a-kind guide offers clear explanations and real-world advice on cystic fibrosis and its management. Here you'll find practical and reassuring information on day-to-day concerns--school, travel, exercise, nutrition, medication--as well as on physiological effects, long-term issues, and prospects for a... |
 | Cystic Fibrosis: Methods and Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) Cystic Fibrosis: Methods and Protocols consolidates cutting-edge in vitro, cellular, and whole animal laboratory protocols into an indispensable resource. From electrophysiology and cell biology, to animal models and gene therapy, this comprehensive set of methods provides the step-by-step instructions needed for investigators to incorporate new approaches into their research programs. Specific... |
 | Cystic Fibrosis (Facts) by Ann Harris, Anne Thomson Cystic Fibrosis: The Facts provides a much needed simple and understandable source book about this disease. It is aimed at those living with Cystic Fibrosis (CF), either themselves or members of their families or their friends. The book explains clearly what is happening to the body in CF, what causes it and what treatment options are available for the different aspects of the disease. There... |
 | The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis by James N. Parker This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to idiopathic pulmonary fibrosis (also alveolocapillary block; cryptogenic... |
 | Taking Flight: Inspirational Stories of Lung Transplantation Lung Transplantation is still relatively new compared to other transplantation surgery. The first successful heart/lung transplant took place in 1981, with the first successful single lung transplant taking place in 1983. It was not until 1986 the first successful double lung transplant takes place. Even more recent is the living lobar transplant which the first successful one being in 1990. The... |
 | Cystic Fibrosis in the 21st Century (Progress in Respiratory Research) Cystic fibrosis used to be thought of as a respiratory and digestive disease, with a uniformly and rapidly fatal outcome. The spectrum of the disease has broadened into the mild atypical case, presenting in middle age, with the potential for complications in virtually every system of the body. In the past few years there has been an explosion of knowledge of the basic science of the defect. The... |
 | One Step at a Time by Jennifer Smith and Bradie Kvinsland "One Step at a Time" is a book, keepsake and guide for coping with a child's hospitalization. It offers a unique way for a parent to ask the right questions, record important medical information, and express joy, fear and hope during a very difficult time. And most important, it encourages parents to take care of themselves physically, emotionally and... |
 | Cystic Fibrosis Care: A Practical Guide by Allison Peebles, Gary J. Connett, Judi C. Maddison, Joan Gavin Written by a team of experts in the field this unique book is a practical guide for the care of cystic fibrosis patients based on day-to-day experience and scientific evidence. Chapters cover every aspect of care from basic daily respiratory and gastroenterology management to the more common complications in cystic fibrosis and includes problem solving more complex issues. Covering all areas of... |
 | Cystic Fibrosis by Margaret Hodson, Duncan Geddes, Andrew Bush This international and authoritative work, which brings together current knowledge in the field of cystic fibrosis, has become established in previous editions as a leading reference in the field. The third edition continues to provide everything that the clinician or allied health professional treating patients with cystic fibrosis will need in a single manageable volume. Thoroughly revised... |
 | Fibrosis Research: Methods and Protocols (Methods in Molecular Medicine) Leading investigators review the highlights of current fibrosis research and the experimental methodologies used uncover the mechanisms that drive it. In their discussion of research methodologies utilizing cultured cells to model various aspects of the fibrotic response in vitro, the authors describe the isolation, characterization, and propagation of mesenchymal cells, and highlight the... |
| © 2008 BrightSurf.com |